Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death

Alvaro Becerra, Cesar Echeverra, Diego Varela, Daniela Sarmiento, Ricardo Armisn, Felipe Nuez-Villena, Mario Montecinos, Felipe Simon

Resultado de la investigación: Article

52 Citas (Scopus)

Resumen

Aims Endothelial dysfunction is decisive in the progression of cardiovascular diseases. Lipopolysaccharide (LPS)-induced reactive oxygen species (ROS)-mediated endothelial cell death is a main feature observed in inflammation secondary to endotoxaemia, emerging as a leading cause of death among critically ill patients in intensive care units. However, the molecular mechanism underlying LPS-induced endothelial cell death is not well understood. Transient receptor protein melastatin 4 (TRPM4) is an ion channel associated with cell death that is expressed in endothelium and modulated by ROS. Here, we investigate the role of TRPM4 in LPS-induced endothelial cell death, testing whether suppression of the expression of TRPM4 confers endothelial cell resistance to LPS challenge. Methods and resultsUsing primary cultures of human umbilical vein endothelial cells (HUVEC), we demonstrate that TRPM4 is critically involved in LPS-induced endothelial cell death. HUVEC exposed to LPS results in Na-dependent cell death. Pharmacological inhibition of TRPM4 with 9-phenanthrol or glibenclamide protects endothelium against LPS exposure for 48 h. Furthermore, TRPM4-like currents increase in cells pre-treated with LPS and inhibited with glibenclamide. Of note, suppression of TRPM4 expression by siRNA or suppression of its activity in a dominant negative mutant is effective in decreasing LPS-induced endothelial cell death when cells are exposed to LPS for 2430 h. ConclusionTRPM4 is critically involved in LPS-induced endothelial cell death. These results demonstrate that either pharmacological inhibition of TRPM4, suppression of TRPM4 expression, or inhibition of TRPM4 activity are able to protect endothelium against LPS injury. These results are useful in sepsis drug design and development of new strategies for sepsis therapy.

Idioma originalEnglish
Páginas (desde-hasta)677-684
Número de páginas8
PublicaciónCardiovascular Research
Volumen91
N.º4
DOI
EstadoPublished - 1 sep 2011

Huella dactilar

Lipopolysaccharides
Cell Death
Endothelial Cells
Proteins
Endothelium
Glyburide
Human Umbilical Vein Endothelial Cells
Reactive Oxygen Species
Sepsis
Pharmacology
Endotoxemia
Drug Design
Ion Channels
Critical Illness
Small Interfering RNA
Intensive Care Units
Cause of Death
Cardiovascular Diseases
Inflammation
Wounds and Injuries

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)
  • Physiology

Citar esto

Becerra, Alvaro ; Echeverra, Cesar ; Varela, Diego ; Sarmiento, Daniela ; Armisn, Ricardo ; Nuez-Villena, Felipe ; Montecinos, Mario ; Simon, Felipe. / Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death. En: Cardiovascular Research. 2011 ; Vol. 91, N.º 4. pp. 677-684.
@article{bd8bb3bac8454541bcf619cfcbd03273,
title = "Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death",
abstract = "Aims Endothelial dysfunction is decisive in the progression of cardiovascular diseases. Lipopolysaccharide (LPS)-induced reactive oxygen species (ROS)-mediated endothelial cell death is a main feature observed in inflammation secondary to endotoxaemia, emerging as a leading cause of death among critically ill patients in intensive care units. However, the molecular mechanism underlying LPS-induced endothelial cell death is not well understood. Transient receptor protein melastatin 4 (TRPM4) is an ion channel associated with cell death that is expressed in endothelium and modulated by ROS. Here, we investigate the role of TRPM4 in LPS-induced endothelial cell death, testing whether suppression of the expression of TRPM4 confers endothelial cell resistance to LPS challenge. Methods and resultsUsing primary cultures of human umbilical vein endothelial cells (HUVEC), we demonstrate that TRPM4 is critically involved in LPS-induced endothelial cell death. HUVEC exposed to LPS results in Na-dependent cell death. Pharmacological inhibition of TRPM4 with 9-phenanthrol or glibenclamide protects endothelium against LPS exposure for 48 h. Furthermore, TRPM4-like currents increase in cells pre-treated with LPS and inhibited with glibenclamide. Of note, suppression of TRPM4 expression by siRNA or suppression of its activity in a dominant negative mutant is effective in decreasing LPS-induced endothelial cell death when cells are exposed to LPS for 2430 h. ConclusionTRPM4 is critically involved in LPS-induced endothelial cell death. These results demonstrate that either pharmacological inhibition of TRPM4, suppression of TRPM4 expression, or inhibition of TRPM4 activity are able to protect endothelium against LPS injury. These results are useful in sepsis drug design and development of new strategies for sepsis therapy.",
keywords = "Cell death, Endothelium, Inflammation, Lipopolysaccharide, TRPM4",
author = "Alvaro Becerra and Cesar Echeverra and Diego Varela and Daniela Sarmiento and Ricardo Armisn and Felipe Nuez-Villena and Mario Montecinos and Felipe Simon",
year = "2011",
month = "9",
day = "1",
doi = "10.1093/cvr/cvr135",
language = "English",
volume = "91",
pages = "677--684",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "4",

}

Becerra, A, Echeverra, C, Varela, D, Sarmiento, D, Armisn, R, Nuez-Villena, F, Montecinos, M & Simon, F 2011, 'Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death', Cardiovascular Research, vol. 91, n.º 4, pp. 677-684. https://doi.org/10.1093/cvr/cvr135

Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death. / Becerra, Alvaro; Echeverra, Cesar; Varela, Diego; Sarmiento, Daniela; Armisn, Ricardo; Nuez-Villena, Felipe; Montecinos, Mario; Simon, Felipe.

En: Cardiovascular Research, Vol. 91, N.º 4, 01.09.2011, p. 677-684.

Resultado de la investigación: Article

TY - JOUR

T1 - Transient receptor potential melastatin 4 inhibition prevents lipopolysaccharide-induced endothelial cell death

AU - Becerra, Alvaro

AU - Echeverra, Cesar

AU - Varela, Diego

AU - Sarmiento, Daniela

AU - Armisn, Ricardo

AU - Nuez-Villena, Felipe

AU - Montecinos, Mario

AU - Simon, Felipe

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Aims Endothelial dysfunction is decisive in the progression of cardiovascular diseases. Lipopolysaccharide (LPS)-induced reactive oxygen species (ROS)-mediated endothelial cell death is a main feature observed in inflammation secondary to endotoxaemia, emerging as a leading cause of death among critically ill patients in intensive care units. However, the molecular mechanism underlying LPS-induced endothelial cell death is not well understood. Transient receptor protein melastatin 4 (TRPM4) is an ion channel associated with cell death that is expressed in endothelium and modulated by ROS. Here, we investigate the role of TRPM4 in LPS-induced endothelial cell death, testing whether suppression of the expression of TRPM4 confers endothelial cell resistance to LPS challenge. Methods and resultsUsing primary cultures of human umbilical vein endothelial cells (HUVEC), we demonstrate that TRPM4 is critically involved in LPS-induced endothelial cell death. HUVEC exposed to LPS results in Na-dependent cell death. Pharmacological inhibition of TRPM4 with 9-phenanthrol or glibenclamide protects endothelium against LPS exposure for 48 h. Furthermore, TRPM4-like currents increase in cells pre-treated with LPS and inhibited with glibenclamide. Of note, suppression of TRPM4 expression by siRNA or suppression of its activity in a dominant negative mutant is effective in decreasing LPS-induced endothelial cell death when cells are exposed to LPS for 2430 h. ConclusionTRPM4 is critically involved in LPS-induced endothelial cell death. These results demonstrate that either pharmacological inhibition of TRPM4, suppression of TRPM4 expression, or inhibition of TRPM4 activity are able to protect endothelium against LPS injury. These results are useful in sepsis drug design and development of new strategies for sepsis therapy.

AB - Aims Endothelial dysfunction is decisive in the progression of cardiovascular diseases. Lipopolysaccharide (LPS)-induced reactive oxygen species (ROS)-mediated endothelial cell death is a main feature observed in inflammation secondary to endotoxaemia, emerging as a leading cause of death among critically ill patients in intensive care units. However, the molecular mechanism underlying LPS-induced endothelial cell death is not well understood. Transient receptor protein melastatin 4 (TRPM4) is an ion channel associated with cell death that is expressed in endothelium and modulated by ROS. Here, we investigate the role of TRPM4 in LPS-induced endothelial cell death, testing whether suppression of the expression of TRPM4 confers endothelial cell resistance to LPS challenge. Methods and resultsUsing primary cultures of human umbilical vein endothelial cells (HUVEC), we demonstrate that TRPM4 is critically involved in LPS-induced endothelial cell death. HUVEC exposed to LPS results in Na-dependent cell death. Pharmacological inhibition of TRPM4 with 9-phenanthrol or glibenclamide protects endothelium against LPS exposure for 48 h. Furthermore, TRPM4-like currents increase in cells pre-treated with LPS and inhibited with glibenclamide. Of note, suppression of TRPM4 expression by siRNA or suppression of its activity in a dominant negative mutant is effective in decreasing LPS-induced endothelial cell death when cells are exposed to LPS for 2430 h. ConclusionTRPM4 is critically involved in LPS-induced endothelial cell death. These results demonstrate that either pharmacological inhibition of TRPM4, suppression of TRPM4 expression, or inhibition of TRPM4 activity are able to protect endothelium against LPS injury. These results are useful in sepsis drug design and development of new strategies for sepsis therapy.

KW - Cell death

KW - Endothelium

KW - Inflammation

KW - Lipopolysaccharide

KW - TRPM4

UR - http://www.scopus.com/inward/record.url?scp=80052002645&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvr135

DO - 10.1093/cvr/cvr135

M3 - Article

C2 - 21565835

AN - SCOPUS:80052002645

VL - 91

SP - 677

EP - 684

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 4

ER -